These include CD19-targeting CAR T cells for relapsed refractory large B cell lymphoma (LBCL), follicular lymphoma, mantle cell lymphoma (MCL) and acute lymphoblastic leukaemia (ALL), and B cell maturation antigen (BCMA)-targeting products for relapsed refractory multiple myeloma [6, 7]. This evidence concerns the gene TNFRSF17 and AL amyloidosis.